Acne Vulgaris Market Forecast to 2034: Regulatory Approvals, Disease Prevalence, Clinical Research, Treatment Options, Key Industry Players - DelveInsight Analysis

Leading acne vulgaris companies, including Ortho Dermatologics, Bausch Health, Galderma Labs, Timber Pharmaceuticals, BioPharmX, Kintor Pharma, Botanix Pharmaceuticals, Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation and others, are aggressively pursuing the treatment space.

Acne vulgaris treatment market

(Albany, USA) DelveInsight's extensive report, "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2034," offers a detailed study of acne vulgaris. The report features historical and projected epidemiological data covering total prevalent cases of acne vulgaris, total prevalent cases diagnosed, prevalent cases diagnosed by gender, and prevalent cases diagnosed by severity.

This comprehensive acne vulgaris market analysis presents current treatment approaches in seven major markets, emerging treatment candidates, individual treatment market shares, and current and projected market size from 2020 to 2034. The report also explores current treatment protocols, market drivers, barriers, and unmet medical needs to identify key opportunities and assess the underlying market potential.

Discover comprehensive insights into the Acne Vulgaris market. Explore drug adoption patterns, treatment approaches, and epidemiological trends with detailed Acne Vulgaris market forecasts. Click here to gain a competitive advantage with medical innovations @ Acne vulgaris market size

Key Findings from the Acne Vulgaris Market Report

• The 7MM Acne Vulgaris market is valued at approximately USD 4,256 million in 2023.
• In 2023, the United States will lead the 7MM acne vulgaris market with approximately USD 2,949 million, and is projected to further increase by 2034.
• December 2024: UCB Biopharma SRL has initiated a Phase 3, open-label, parallel-group, multicenter extension study evaluating long-term treatment with bimekizumab in patients with moderate to severe hidradenitis suppurativa (HS).
• December 2024: Incyte Corporation initiated a study to evaluate the long-term safety and efficacy of povorcitinib in patients with moderate-to-severe hidradenitis suppurativa who completed 54 weeks of treatment in the Phase 3 parent trials (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
• June 2024: Zhejiang Yangguang Martial Pharmaceutical Co., Ltd. initiated a multicenter, randomized, double-blind, vehicle-controlled clinical trial evaluating clascoterone cream 1% for facial acne vulgaris over a 12-week period.
• June 2024: Sanofi initiated a Phase I/II randomized, placebo-controlled, multi-arm, dose-ranging study to evaluate the safety, efficacy, and immunogenicity of its acne mRNA vaccine candidate in adults with moderate to severe acne.
• June 2024: AbbVie initiated an international, multicenter, double-blind, randomized, parallel-group, controlled trial to evaluate the safety and efficacy of ELAPR002f injectable gel in adult participants with atrophic acne scars.
• June 2024: UCB Biopharma SRL has initiated a Phase 3, open-label, parallel-group, multicenter extension study evaluating long-term treatment with bimekizumab in patients with moderate to severe hidradenitis suppurativa.
• June 2024: Incyte Corporation initiated a Phase 3 double-blind study to evaluate the long-term safety and efficacy of povorcitinib in patients with moderate-to-severe hidradenitis suppurativa who completed 54 weeks of treatment in the initial Phase 3 study.
• A Japanese study showed that the prevalence of acne vulgaris among students was 58.6%, with the average age of onset being 13.3 years.
• In Italy, "mild acne" was the most common form, affecting 92% of adult women, 82% of adult men, 89% of teenage women and 77% of teenage men.
• A German employee survey indicates an overall acne prevalence of 4.2%, while other studies have shown prevalence in adolescents (ages 9–20) to be up to 95%.
• Key acne vulgaris companies include Ortho Dermatologics, Bausch Health, Galderma Labs, Timber Pharmaceuticals, BioPharmX, Kintor Pharma, Botanix Pharmaceuticals, Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation, and others.
• Promising acne vulgaris treatments in development include anifrolumab, CFZ533, bimekizumab, povorcitinib, clascoterone, DMT310, Winlevi (clascoterone) 1% and Duac Gel, erythromycin 4% topical gel formulation, and ASC40.

Gain deeper insights into the Acne Vulgaris market: Analyze treatment trends, treatment adoption patterns, and epidemiological shifts through detailed Acne Vulgaris market forecasts. Click here to plan your future strategies @Insights into the epidemiology of acne vulgaris

Overview of Acne Vulgaris

Acne vulgaris is a common chronic skin disease that develops when hair follicles become clogged with oil, dead skin cells and bacteria, causing inflammation. It primarily affects adolescents and young adults, but the condition can continue into adulthood. Multiple factors influence the development of acne, including hormonal fluctuations, excess sebum production, bacterial growth (Propionibacterium acnes), genetic predisposition and lifestyle factors.

The condition manifests itself in various forms – whiteheads, blackheads, papules, pustules, nodules and cysts – and appears primarily on the face, chest, shoulders and back. Mild cases may respond to over-the-counter medications, but moderate to severe acne usually requires prescription medications such as topical retinoids, benzoyl peroxide and antibiotics, or oral treatments such as isotretinoin or hormone therapy.

Acne can have a significant impact on self-esteem and quality of life, so prompt treatment is crucial to prevent scarring, post-inflammatory hyperpigmentation, and psychological distress. Treatment options continue to expand thanks to advances in dermatology, such as laser therapy and targeted biologics. Lifestyle modifications, such as balanced nutrition, proper skin care practices, and stress management, can complement medical treatment. Although not life-threatening, the social and emotional impact of acne makes it an important focus for ongoing dermatology research and innovation.

Insights into the epidemiology of acne vulgaris

• Total number of epidemic cases
• Total diagnosed epidemic cases
• Prevalent cases diagnosed by gender
• Diagnosed prevalent cases by severity
• Treated cases

Navigate the complexities of the Acne Vulgaris market: Access insights into treatment trends, therapeutic approaches, and epidemiological patterns through a comprehensive Acne Vulgaris market forecast. Click here to learn more @Acne vulgaris treatment market

Acne vulgaris pharmaceutical market

As per DelveInsight forecasts, the 7MM acne vulgaris market is expected to show positive growth during the forecast period (2024-2034). This growth is primarily due to the increasing prevalence of acne vulgaris, improved awareness and diagnosis rates, and upcoming product launches. The expected increase in acne vulgaris treatment cases in the United States is due to factors such as increased awareness, advancements in treatment, lifestyle changes, and evolving societal views towards skincare and self-care. Collectively, these factors will increase the demand for acne treatment and management services. These projections may vary during the forecast period (2024-2034).

Treatment for acne vulgaris

Acne treatment approaches vary depending on the patient's age and sex, the extent and severity of acne, duration of symptoms, and response to previous interventions. Mild acne treatments typically include topical anti-acne preparations, laser therapy, and phototherapy. Moderate acne often requires antibiotics such as tetracycline and antiandrogens such as oral contraceptives. Severe acne may require oral isotretinoin therapy. Azelaic acid is a natural acid produced by yeast and has antibacterial properties. Applying 20% ​​azelaic acid cream or gel twice daily has been shown to be as effective as many traditional acne treatments.

Acne Vulgaris Market Insights

Numerous treatments exist for acne vulgaris, but there remains a need for more effective long-term maintenance therapies to prevent recurrence and minimize the risk of scarring. Some patients with acne vulgaris do not respond adequately to existing treatments, such as antibiotics, topical retinoids, and hormonal therapy, creating a demand for alternative options for treatment-resistant cases. Many acne treatments, especially oral medications like isotretinoin, can cause significant side effects, highlighting the need for therapies that effectively treat acne while minimizing side effects, especially in adolescents and young adults. The heterogeneous nature of acne vulgaris and the different treatment responses across individuals have led to an increased demand for individualized treatment approaches that take into account factors such as acne severity, skin type, hormonal status, and underlying comorbidities.

Unlock Comprehensive Insights into the Acne Vulgaris Market: Explore treatment adoption patterns, therapeutic approaches, and epidemiological trends with our proprietary Acne Vulgaris market forecast. Click Here @Acne Vulgaris Market Drivers and Barriers

Over-the-counter acne medications

Acreef: Galderma Research InstituteAKLIEF (trifarotene) cream, 0.005% is indicated for the topical treatment of acne. It selectively targets retinoic acid receptor (RAR) gamma, the most prevalent RAR in the skin, making it the first topical retinoid with this specific action. Trifarotene is the first new retinoid molecule to receive FDA approval for the treatment of acne in over 20 years. AKLIEF cream has been specifically studied and proven effective in the treatment of both facial (forehead, cheeks, nose, chin) and torso (chest, shoulders, back) acne, providing health care professionals and patients with an additional treatment option.

ARAZLO: Ortho Dermatologics/Bausch HealthARAZLO (tazarotene) lotion, 0.045% is a prescription medication applied topically to treat acne in people 9 years of age and older. It effectively addresses a variety of acne symptoms, including blackheads, whiteheads, and other types of acne. Notably, ARAZLO is the first tazarotene acne medication available in lotion form, providing powerful effectiveness that is well tolerated.

CABTREO: Ortho Dermatologics/Bausch HealthCABTREO (clindamycin phosphate, adapalene, benzoyl peroxide) topical gel 1.2%/0.15%/3.1% is a prescription medication specially formulated for topical application to treat acne vulgaris in adults and children over the age of 12. It is the first and only FDA-approved fixed-dose triple combination topical treatment for acne that combines clindamycin phosphate, adapalene, and benzoyl peroxide to comprehensively address the symptoms of acne.

Emerging Treatments for Acne Vulgaris

The acne vulgaris medication market is expected to evolve gradually, mainly due to the limited number of emerging therapies in this therapeutic area. Major industry players such as BioPharmX, Kintor Pharma, and Botanix Pharmaceuticals have shown significant interest in this condition and are actively working on developing potential treatments.

BPX-01: Timber Pharmaceuticals/BioPharmXBPX-01 (topical minocycline, 2%) is being developed for the treatment of moderate to severe acne. In a Phase 2b clinical trial, BPX-01 demonstrated a statistically significant reduction in acne lesions with no treatment-related serious adverse events. BPX-01 is a hydrophilic topical gel containing fully solubilized minocycline that can penetrate the skin and deliver the antibiotic directly to the pilosebaceous unit where acne originates. The drug is currently in Phase II clinical development for the treatment of acne.

KX-826: Quinter PharmaKintor Pharmaceuticals is developing KX-826 for acne vulgaris. The drug is being developed in a topical formulation for patients with mild to moderate acne. The company is preparing an IND application to begin clinical development.

BTX 1503: Botanix PharmaceuticalsBotanix Pharmaceuticals is developing BTX 1503, an innovative topical treatment for moderate to severe acne. The formulation utilizes synthetic cannabidiol as the active drug ingredient, combined with Botanix's proprietary Permetrex drug delivery technology. The company has announced Phase II results and is currently preparing for Phase III clinical trials for the treatment of acne.

Scope of the Acne Vulgaris Market Report

• Coverage: 7MM
• Acne Vulgaris 企業: Ortho Dermatologics、Bausch Health、Galderma Labs、Timber Pharmaceuticals、BioPharmX、Kintor Pharma、Botanix Pharmaceuticals、Dermata Therapeutics、AstraZeneca、Novartis Pharmaceuticals、UCB Pharma、Incyte Corporation など
• Treatments for acne vulgaris: Clascoterone, DMT310, Winlevi (clascoterone) 1% and Duac Gel, erythromycin 4% topical gel formulation, ASC40, etc.
• Acne Vulgaris Market Dynamics: Market Drivers and Barriers
• Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG matrix, market entry strategy
• Unmet Needs, KOL Opinions, Analyst Opinions, Market Access & Reimbursement

Gain a strategic advantage in the Acne Vulgaris market. Explore comprehensive pharmaceutical insights, therapeutic advancements, and epidemiological forecasts with our detailed Acne Vulgaris market forecast. Click here to lead the therapeutic innovation @Clinical Trials and Treatment Evaluations for Acne Vulgaris

table of contents

1. Key Insights
2. Report Introduction
3. Acne Vulgaris Market Overview
4. Epidemiology and market methods
5. executive summary
6. Main events of acne vulgaris
7. Disease Background and Overview: Acne Vulgaris
8. Epidemiology and prevalence
9. The patient journey
10. Over-the-counter treatments
11. New Treatments
12. Acne Vulgaris: Seven Key Markets Analysis
13. Key opinion leader perspectives
14. Unmet needs
15. SWOT Analysis
16. Acne Vulgaris Market Access and Reimbursement
17. appendix
18. DelveInsight Features
19. Disclaimer

About DelveInsight

DelveInsight is a leading healthcare business consultancy and market research firm focused on life sciences. The company supports pharmaceutical companies with comprehensive end-to-end solutions to improve performance. DelveInsight also offers healthcare consulting services to facilitate market analysis to accelerate business growth and overcome challenges with a practical, result-oriented approach.